Literature DB >> 21504237

Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.

Tallal Younis1, Chris Skedgel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21504237     DOI： 10.2165/11588350-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  26 in total

1.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

Authors:  S S Ellenberg; R Temple
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

Review 2.  Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.

Authors:  Dirk Bassler; Matthias Briel; Victor M Montori; Melanie Lane; Paul Glasziou; Qi Zhou; Diane Heels-Ansdell; Stephen D Walter; Gordon H Guyatt; David N Flynn; Mohamed B Elamin; Mohammad Hassan Murad; Nisrin O Abu Elnour; Julianna F Lampropulos; Amit Sood; Rebecca J Mullan; Patricia J Erwin; Clare R Bankhead; Rafael Perera; Carolina Ruiz Culebro; John J You; Sohail M Mulla; Jagdeep Kaur; Kara A Nerenberg; Holger Schünemann; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Heiner C Bucher; Alain J Nordmann; Heike Raatz; Suzana Alves da Silva; Fabio Tuche; Brigitte Strahm; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Paul J Karanicolas; Karen E A Burns; Per Olav Vandvik; Fernando Coto-Yglesias; Pedro Paulo M Chrispim; Tim Ramsay
Journal:  JAMA       Date:  2010-03-24       Impact factor: 56.272

3.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 4.  Trastuzumab--mechanism of action and use in clinical practice.

Authors:  Clifford A Hudis
Journal:  N Engl J Med       Date:  2007-07-05       Impact factor: 91.245

5.  Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.

Authors:  Peter S Hall; Claire Hulme; Christopher McCabe; Yemi Oluboyede; Jeff Round; David A Cameron
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

Review 7.  Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Issa J Dahabreh; Helen Linardou; Fotios Siannis; George Fountzilas; Samuel Murray
Journal:  Oncologist       Date:  2008-06

8.  Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.

Authors:  J Alasdair Millar; Michael J Millward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 9.  Design and analysis issues for economic analysis alongside clinical trials.

Authors:  Deborah A Marshall; Margaret Hux
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

10.  The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Kojiro Shimozuma; Yasuo Ohashi; Kiichiro Tsutani
Journal:  Breast Cancer Res Treat       Date:  2007-07-28       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.